Reata Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for SKYCLARYS™ (omaveloxolone) to treat Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. This development is crucial for the approximately 5,000 diagnosed patients in the United States with this ultra-rare, inherited neuro-degenerative disorder, commonly diagnosed during […]
